Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2009

View Archived Issues

Reduced fractures with denosumab in postmenopausal women and men with prostate cancer

Studies with HC-056456 reveal CatSper channels as a target for blocking fertility

rAAV1-AAT gene therapy shows promise for future development in phase I trial

Doxorubicin derivative INNO-206 more potent than free doxorubicin in vivo

Merck & Co. to assess safety/efficacy of MK-2578 in kidney disease patients in phase II trial

Safety and efficacy of JTT-130 to be evaluated in obese type 2 diabetic patients

Bayer relegates clinical trials for alemtuzumab to Genzyme Japan

Bevacizumab plus erlotinib therapy shows activity in phase II clinical trial in HCC

Can-Fite BioPharma reports results from its phase II CF-101 trial in psoriasis

Opexa Therapeutics reports additional data with Tovaxin for multiple sclerosis

Novel PARP inhibitors presented by AstraZeneca for cancer therapy

R-Tech Ueno presents VAP-1 inhibitors for macular edema and other eye conditions

Akela undergoes corporate restructuring

PPARgamma agonists for the treatment of AD described by GlaxoSmithKline

Panacea Biotec discloses DPP-IV inhibitors for the treatment of type 2 diabetes

NeuroSearch patents novel dopamine and serotonin receptor ligands as antipsychotics

Luminex receives 510(k) clearance for new cystic fibrosis test

XenoPort reports results from a safety and tolerability trial of arbaclofen

LigoCyte initiates phase I/II study of nasally delivered dry powder norovirus vaccine

Shire provides update on velaglucerase alfa for Gaucher's disease

GlycoMimetics begins pilot study of GMI-1070 in sickle cell patients

Dor BioPharma receives NIH grant to support phase I/II DOR-201 trial in radiation enteritis

Evotec commences phase I trial of EVT-103

Ark Therapeutics receives feedback from MHRA on EG-013

Bayer Schering submits IND for phase I MN-IC trial, triggering milestone payments